Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine for HVPG in Advanced Chronic Liver Disease
NCT04455464Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of midodrine in chronic liver disease (CLD) and acute-on-chronic liver failure (ACLF), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Hepatic Venous Pressure Gradient response at 3 hours. Started Jul 2020; status: completed.
02
Drugs
midodrine
03
Conditions
chronic liver disease (CLD)acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT04455464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455464.